CN103476434A - 用于放射治疗的177镥标记的铃蟾肽类似物 - Google Patents

用于放射治疗的177镥标记的铃蟾肽类似物 Download PDF

Info

Publication number
CN103476434A
CN103476434A CN2011800561585A CN201180056158A CN103476434A CN 103476434 A CN103476434 A CN 103476434A CN 2011800561585 A CN2011800561585 A CN 2011800561585A CN 201180056158 A CN201180056158 A CN 201180056158A CN 103476434 A CN103476434 A CN 103476434A
Authority
CN
China
Prior art keywords
phe
gln
trp
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800561585A
Other languages
English (en)
Chinese (zh)
Inventor
桑德拉·博尔科斯基
洛萨尔巴·曼西
赫尔马特·梅克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsspital Basel USB
Life Molecular Imaging SA
Original Assignee
Universitaetsspital Basel USB
Piramal Imaging SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsspital Basel USB, Piramal Imaging SA filed Critical Universitaetsspital Basel USB
Publication of CN103476434A publication Critical patent/CN103476434A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800561585A 2010-11-22 2011-11-21 用于放射治疗的177镥标记的铃蟾肽类似物 Pending CN103476434A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10075743.4 2010-11-22
EP10075743 2010-11-22
PCT/EP2011/070553 WO2012069410A1 (en) 2010-11-22 2011-11-21 177lutetium-labeled bombesin analogs for radiotherapy

Publications (1)

Publication Number Publication Date
CN103476434A true CN103476434A (zh) 2013-12-25

Family

ID=45001762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800561585A Pending CN103476434A (zh) 2010-11-22 2011-11-21 用于放射治疗的177镥标记的铃蟾肽类似物

Country Status (16)

Country Link
US (1) US20140023585A1 (enExample)
EP (1) EP2643024A1 (enExample)
JP (1) JP2014500262A (enExample)
KR (1) KR20140053819A (enExample)
CN (1) CN103476434A (enExample)
AU (1) AU2011333948A1 (enExample)
BR (1) BR112013012503A2 (enExample)
CA (1) CA2818694A1 (enExample)
EA (1) EA026443B1 (enExample)
IL (1) IL226498A0 (enExample)
IN (1) IN2013MN01188A (enExample)
MX (1) MX2013005697A (enExample)
NZ (1) NZ610740A (enExample)
PH (1) PH12013501018A1 (enExample)
SG (1) SG190371A1 (enExample)
WO (1) WO2012069410A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106039327A (zh) * 2016-06-14 2016-10-26 宁波益格爱生物科技有限公司 一种grpr靶向性分子探针及其制备方法
CN117919452A (zh) * 2023-03-09 2024-04-26 中国科学院宁波材料技术与工程研究所 一种亚细胞器主动靶向成像探针及其制备方法
WO2025119203A1 (zh) * 2023-12-05 2025-06-12 烟台蓝纳成生物技术有限公司 一种异二聚体放射性核素偶联药物、制备及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
PL2900279T3 (pl) 2012-09-25 2020-05-18 Advanced Accelerator Applications Usa, Inc. Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego
US20190358351A1 (en) * 2016-11-17 2019-11-28 Minerva Imaging Aps 177-lu labeled active site inhibited factor vii
US20250339567A1 (en) * 2019-12-19 2025-11-06 Technische Universität München Compounds with improved pharmacokinetics for imaging and therapy of cancer
EP4282439A1 (en) * 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109332A1 (en) * 2008-03-07 2009-09-11 Universitätsspital Bern Bombesin analog peptide antagonist conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109332A1 (en) * 2008-03-07 2009-09-11 Universitätsspital Bern Bombesin analog peptide antagonist conjugates

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106039327A (zh) * 2016-06-14 2016-10-26 宁波益格爱生物科技有限公司 一种grpr靶向性分子探针及其制备方法
CN117919452A (zh) * 2023-03-09 2024-04-26 中国科学院宁波材料技术与工程研究所 一种亚细胞器主动靶向成像探针及其制备方法
WO2025119203A1 (zh) * 2023-12-05 2025-06-12 烟台蓝纳成生物技术有限公司 一种异二聚体放射性核素偶联药物、制备及其应用

Also Published As

Publication number Publication date
US20140023585A1 (en) 2014-01-23
EA201300611A1 (ru) 2014-04-30
CA2818694A1 (en) 2012-05-31
NZ610740A (en) 2015-08-28
PH12013501018A1 (en) 2017-08-23
IN2013MN01188A (enExample) 2015-07-10
BR112013012503A2 (pt) 2016-11-08
IL226498A0 (en) 2013-07-31
KR20140053819A (ko) 2014-05-08
WO2012069410A1 (en) 2012-05-31
JP2014500262A (ja) 2014-01-09
EA026443B1 (ru) 2017-04-28
MX2013005697A (es) 2014-08-01
AU2011333948A1 (en) 2013-06-06
SG190371A1 (en) 2013-06-28
EP2643024A1 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
EP2252628B1 (en) Bombesin analog peptide antagonist conjugates
JP2954354B2 (ja) 造影用のテクネチウム‐９９ｍ標識ペプチド
CN103476434A (zh) 用于放射治疗的177镥标记的铃蟾肽类似物
IE67637B1 (en) Labeled Polypeptide Derivatives
CN107382890A (zh) 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
JPH10501241A (ja) 造影用テクネチウム−９９ｍ標識ペプチド
BR112015006453B1 (pt) Antagonista de grpr radiomarcado e composição terapêutica que o compreende
JP2001511152A (ja) 悪性ヒト腫瘍の検出および位置特定法
KR20230027004A (ko) 구리-함유 테라그노스틱 화합물 및 사용 방법
WO1995022341A1 (en) Labelled peptide compounds
Bugaj et al. Radiotherapeutic efficacy of 153Sm-CMDTPA-Tyr3-octreotate in tumor-bearing rats☆
US6855308B2 (en) PACAP compositions and methods for tumor imaging and therapy
CA2518406A1 (en) Thiol-mediated drug attachment to targeting peptides
WO1999062563A2 (en) Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
CN114845742A (zh) 用于癌症成像和治疗的经改性的grpr拮抗剂肽
HK1192487A (en) 177 lutetium-labeled bombesin analogs for radiotherapy
WO1997031657A2 (en) Use of labelled cck-b receptor ligands for the detection and localization of malignant human tumors
US5952464A (en) Labelled peptide compounds
WO2024046469A1 (zh) 环肽及其制备方法、包括其的复合物、及其用途
AU2002342104A1 (en) PACAP compositions and methods for tumor imaging and therapy
CZ279099A3 (cs) Způsob detekce a lokalizaci lidských maligních tumorů

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192487

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131225

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192487

Country of ref document: HK